These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 83969)
1. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes. Schirrmacher V; Bosslet K; Shantz G; Clauer K; Hübsch D Int J Cancer; 1979 Feb; 23(2):245-52. PubMed ID: 83969 [TBL] [Abstract][Full Text] [Related]
2. Different expression of Lyt differentiation antigens and cell surface glycoproteins by a murine T lymphoma line and its highly metastatic variant. Altevogt P; Kurnick JT; Kimura AK; Bosslet K; Schirrmacher V Eur J Immunol; 1982 Apr; 12(4):300-7. PubMed ID: 6124426 [TBL] [Abstract][Full Text] [Related]
3. Antigenic variation in cancer metastasis: immune escape versus immune control. Schirrmacher V; Fogel M; Russmann E; Bosslet K; Altevogt P; Beck L Cancer Metastasis Rev; 1982; 1(3):241-74. PubMed ID: 6985248 [TBL] [Abstract][Full Text] [Related]
4. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VI. Similar specificity patterns of protective anti-tumor immunity in vivo and of cytolytic T cells in vitro. Bosslet K; Schirrmacher V; Shantz G Int J Cancer; 1979 Sep; 24(3):303-13. PubMed ID: 314938 [No Abstract] [Full Text] [Related]
5. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. X. Immunoselection of tumor variants differing in tumor antigen expression and metastatic capacity. Schirrmacher V; Bosslet K Int J Cancer; 1980 Jun; 25(6):781-8. PubMed ID: 14768708 [TBL] [Abstract][Full Text] [Related]
6. Suggestive evidence that the highly metastatic variant ESb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage. Larizza L; Schirrmacher V; Graf L; Pflüger E; Peres-Martinez M; Stöhr M Int J Cancer; 1984 Nov; 34(5):699-707. PubMed ID: 6500746 [TBL] [Abstract][Full Text] [Related]
7. New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells. von Hoegen P; Altevogt P; Schirrmacher V Cell Immunol; 1987 Oct; 109(2):338-48. PubMed ID: 3117377 [TBL] [Abstract][Full Text] [Related]
8. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state. Weinhold KJ; Wheelock EF Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice. Fuyama S; Yamamoto H; Fujii Y; Arai S Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480 [TBL] [Abstract][Full Text] [Related]
10. Analysis of protective and cytotoxic immune responses in vivo against metabolically inactivated and untreated cells of a mutagenized tumor line (requirements for tumor immunogenicity). Wehrmaker A; Lehmann V; Dröge W Cell Immunol; 1986 Sep; 101(2):290-8. PubMed ID: 2428514 [TBL] [Abstract][Full Text] [Related]
11. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. V. Transfer of protective immunity with H-2 identical immune T cells from B10.D2 mice. Schirrmacher V Int J Cancer; 1979 Jul; 24(1):80-6. PubMed ID: 314423 [No Abstract] [Full Text] [Related]
12. In vitro reactivity of splenic lymphocytes from normal and UV-irradiated mice against syngeneic UV-induced tumors. Fortner GW; Kripke ML J Immunol; 1977 Apr; 118(4):1483-7. PubMed ID: 66296 [TBL] [Abstract][Full Text] [Related]
13. Cell-mediated immunity to leukemia virus- and tumor-associated antigens in mice. Herberman RB; Holden HT; Ting CC; Lavrin DL; Kirchner H Cancer Res; 1976 Feb; 36(2 pt 2):615-21. PubMed ID: 56223 [TBL] [Abstract][Full Text] [Related]
14. Resistance of metastatic tumor variants to tumor-specific cytotoxic T-lymphocytes not due to defects in expression of restricting major histocompatibility complex molecules in murine cells. Altevogt P; Leidig S; Heckl-Oestreicher B Cancer Res; 1984 Nov; 44(11):5305-13. PubMed ID: 6333273 [TBL] [Abstract][Full Text] [Related]
15. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level. Sensi M; Orosz CG; Bach FH J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778 [TBL] [Abstract][Full Text] [Related]
16. Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: migration, survival and tumor-protectivity of cytotoxic donor cells. Zangemeister-Wittke U; Schirrmacher V Biotherapy; 1991; 3(4):319-29. PubMed ID: 1786195 [TBL] [Abstract][Full Text] [Related]
17. Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response. Von Hoegen P; Weber E; Schirrmacher V Eur J Immunol; 1988 Aug; 18(8):1159-66. PubMed ID: 2970967 [TBL] [Abstract][Full Text] [Related]
18. Studies on the induction and expression of T cell-mediated immunity. IV. Non-overlapping populations of alloimmune cytotoxic lymphocytes with specificity for tumor-associated antigens and transplantation antigens. Kedar E; Bonavida B J Immunol; 1975 Nov; 115(5):1301-8. PubMed ID: 51889 [TBL] [Abstract][Full Text] [Related]
19. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells. Plata F; Jongeneel V; Cerottini JC; Brunner KT Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429 [TBL] [Abstract][Full Text] [Related]
20. Secondary cell-mediated cytotoxic response to challenge of rats with syngeneic Gross virus-induced lymphoma. Glaser M; Herberman R J Natl Cancer Inst; 1976 Jun; 56(6):1211-5. PubMed ID: 62841 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]